JP2019534867A - カンナビノイド受容体結合リガンドを含む組成物 - Google Patents
カンナビノイド受容体結合リガンドを含む組成物 Download PDFInfo
- Publication number
- JP2019534867A JP2019534867A JP2019516407A JP2019516407A JP2019534867A JP 2019534867 A JP2019534867 A JP 2019534867A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019534867 A JP2019534867 A JP 2019534867A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- thc
- composition according
- receptor binding
- cannabinoid receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191194.6 | 2016-09-28 | ||
| EP16191194 | 2016-09-28 | ||
| EP17168172.9 | 2017-04-26 | ||
| EP17168172 | 2017-04-26 | ||
| PCT/EP2017/074545 WO2018060282A1 (en) | 2016-09-28 | 2017-09-27 | Compositions comprising a cannabinoid receptor binding ligand |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534867A true JP2019534867A (ja) | 2019-12-05 |
| JP2019534867A5 JP2019534867A5 (enExample) | 2020-04-09 |
Family
ID=59966776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516407A Pending JP2019534867A (ja) | 2016-09-28 | 2017-09-27 | カンナビノイド受容体結合リガンドを含む組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190343793A1 (enExample) |
| EP (2) | EP3698785A1 (enExample) |
| JP (1) | JP2019534867A (enExample) |
| KR (1) | KR20190060787A (enExample) |
| CN (1) | CN109803650A (enExample) |
| AU (1) | AU2017333420A1 (enExample) |
| BR (1) | BR112019006194A2 (enExample) |
| CA (1) | CA3036313A1 (enExample) |
| MX (1) | MX2019003544A (enExample) |
| WO (1) | WO2018060282A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021073541A (ja) * | 2016-12-27 | 2021-05-13 | フェイスブック・テクノロジーズ・リミテッド・ライアビリティ・カンパニーFacebook Technologies, Llc | 触覚デバイスの大規模集積化 |
| JP2023543925A (ja) * | 2020-10-05 | 2023-10-18 | マックス バイオロジー カンパニー リミテッド | カンナビノイド含有組成物及び疾患の処置及び予防のための使用 |
| JP2023546649A (ja) * | 2020-09-24 | 2023-11-07 | ニコベンチャーズ トレーディング リミテッド | 製剤 |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| DK2895144T3 (en) | 2012-09-12 | 2017-03-06 | Novaliq Gmbh | SEMIFLUORED ALKAN COMPOSITIONS |
| EP3100722B1 (en) | 2012-09-12 | 2024-03-20 | Novaliq GmbH | Semifluorinated alkanes for use in solubilizing meibum |
| US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| AU2017260444B2 (en) | 2016-05-03 | 2019-05-09 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
| JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
| JP7012075B2 (ja) | 2016-09-22 | 2022-01-27 | ノバリック ゲーエムベーハー | 眼瞼炎の治療に使用するための医薬組成物 |
| JP6869336B2 (ja) | 2016-09-23 | 2021-05-12 | ノバリック ゲーエムベーハー | シクロスポリンを含む眼科用組成物 |
| ES2957559T3 (es) | 2017-04-21 | 2024-01-22 | Dermaliq Therapeutics Inc | Composiciones de yodo |
| WO2018206656A1 (en) | 2017-05-12 | 2018-11-15 | Novaliq Gmbh | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
| KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
| CN111526914A (zh) | 2017-10-04 | 2020-08-11 | 精呼吸股份有限公司 | 电子呼吸致动式直线型液滴输送装置及其使用方法 |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| EP3706843B1 (en) | 2017-11-08 | 2024-06-26 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule |
| JP7353292B2 (ja) | 2018-03-02 | 2023-09-29 | ノバリック ゲーエムベーハー | ネビボロールを含む医薬組成物 |
| US12226422B2 (en) | 2018-04-27 | 2025-02-18 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CA3128224A1 (en) * | 2019-02-01 | 2020-08-06 | Aerie Pharmaceuticals, Inc. | Compounds, compositions and methods for treatment of myopia |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| US12419933B2 (en) | 2019-09-06 | 2025-09-23 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| KR20230142548A (ko) | 2021-02-03 | 2023-10-11 | 에이디에스 테라퓨틱스 엘엘씨 | 국소 안과용 조성물 |
| EP4359046B1 (en) | 2021-06-22 | 2025-08-27 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
| US20250228876A1 (en) * | 2021-10-13 | 2025-07-17 | Pneuma Respiratory, Inc. | Compositions for delivery of cannabinoids |
| CN119768202A (zh) | 2022-07-18 | 2025-04-04 | 精呼吸股份有限公司 | 小步长高分辨率气溶胶生成系统及方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511157A (ja) * | 1995-09-29 | 2000-08-29 | マイネルト,ハッソ | セミフルオロアルカン及びその使用 |
| JP2013513586A (ja) * | 2009-12-14 | 2013-04-22 | ノバリック ゲーエムベーハー | ドライアイ症候群の治療のための医薬組成物 |
| JP2013540140A (ja) * | 2010-10-20 | 2013-10-31 | ノバリック ゲーエムベーハー | 有効成分の送達のための液体医薬組成物 |
| WO2015074137A1 (en) * | 2013-11-20 | 2015-05-28 | Mary Lynch | Compositions and methods for treatment of ocular inflammation and pain |
| WO2016109531A1 (en) * | 2014-12-30 | 2016-07-07 | Axim Biotechnologies, Inc. | Ophthalmic solutions for glaucoma and conjunctivitis treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516333A (zh) | 2006-08-04 | 2009-08-26 | 英西斯治疗学股份有限公司 | 水性屈大麻酚制剂 |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| HUE032158T2 (en) | 2008-10-31 | 2017-09-28 | Univ Mississippi | Process for the preparation of delta9-THC amino acid esters |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| EP3100722B1 (en) * | 2012-09-12 | 2024-03-20 | Novaliq GmbH | Semifluorinated alkanes for use in solubilizing meibum |
| DK2895144T3 (en) * | 2012-09-12 | 2017-03-06 | Novaliq Gmbh | SEMIFLUORED ALKAN COMPOSITIONS |
| WO2015053829A1 (en) | 2013-10-09 | 2015-04-16 | Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
-
2017
- 2017-09-27 US US16/337,617 patent/US20190343793A1/en not_active Abandoned
- 2017-09-27 JP JP2019516407A patent/JP2019534867A/ja active Pending
- 2017-09-27 EP EP20159519.6A patent/EP3698785A1/en not_active Withdrawn
- 2017-09-27 BR BR112019006194A patent/BR112019006194A2/pt not_active IP Right Cessation
- 2017-09-27 CA CA3036313A patent/CA3036313A1/en not_active Withdrawn
- 2017-09-27 AU AU2017333420A patent/AU2017333420A1/en not_active Abandoned
- 2017-09-27 KR KR1020197010976A patent/KR20190060787A/ko not_active Ceased
- 2017-09-27 CN CN201780058931.9A patent/CN109803650A/zh not_active Withdrawn
- 2017-09-27 MX MX2019003544A patent/MX2019003544A/es unknown
- 2017-09-27 WO PCT/EP2017/074545 patent/WO2018060282A1/en not_active Ceased
- 2017-09-27 EP EP17772438.2A patent/EP3518921B1/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511157A (ja) * | 1995-09-29 | 2000-08-29 | マイネルト,ハッソ | セミフルオロアルカン及びその使用 |
| JP2013513586A (ja) * | 2009-12-14 | 2013-04-22 | ノバリック ゲーエムベーハー | ドライアイ症候群の治療のための医薬組成物 |
| JP2013540140A (ja) * | 2010-10-20 | 2013-10-31 | ノバリック ゲーエムベーハー | 有効成分の送達のための液体医薬組成物 |
| WO2015074137A1 (en) * | 2013-11-20 | 2015-05-28 | Mary Lynch | Compositions and methods for treatment of ocular inflammation and pain |
| WO2016109531A1 (en) * | 2014-12-30 | 2016-07-07 | Axim Biotechnologies, Inc. | Ophthalmic solutions for glaucoma and conjunctivitis treatment |
Non-Patent Citations (3)
| Title |
|---|
| AM J DRUG DELIV, vol. 2, no. 4, JPN6021023811, 2004, pages 229 - 240, ISSN: 0004827481 * |
| EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 88, JPN6021023813, 2014, pages 123 - 128, ISSN: 0004827482 * |
| INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 57, JPN6021023814, 2016, pages 417, ISSN: 0004827483 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021073541A (ja) * | 2016-12-27 | 2021-05-13 | フェイスブック・テクノロジーズ・リミテッド・ライアビリティ・カンパニーFacebook Technologies, Llc | 触覚デバイスの大規模集積化 |
| JP2023546649A (ja) * | 2020-09-24 | 2023-11-07 | ニコベンチャーズ トレーディング リミテッド | 製剤 |
| JP2023543925A (ja) * | 2020-10-05 | 2023-10-18 | マックス バイオロジー カンパニー リミテッド | カンナビノイド含有組成物及び疾患の処置及び予防のための使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190060787A (ko) | 2019-06-03 |
| EP3698785A1 (en) | 2020-08-26 |
| AU2017333420A1 (en) | 2019-04-04 |
| BR112019006194A2 (pt) | 2019-06-18 |
| EP3518921A1 (en) | 2019-08-07 |
| CA3036313A1 (en) | 2018-04-05 |
| WO2018060282A1 (en) | 2018-04-05 |
| US20190343793A1 (en) | 2019-11-14 |
| CN109803650A (zh) | 2019-05-24 |
| EP3518921B1 (en) | 2021-08-11 |
| MX2019003544A (es) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3518921B1 (en) | Compositions comprising a cannabinoid receptor binding ligand | |
| JP6397472B2 (ja) | ドライアイ症候群の治療のための医薬組成物 | |
| US9937225B2 (en) | Topical formulations and uses thereof | |
| US20200009137A1 (en) | Topical formulations and uses thereof | |
| WO2017152129A2 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
| HK40036791A (en) | Compositions comprising a cannabinoid receptor binding ligand | |
| HK40008248A (en) | Compositions comprising a cannabinoid receptor binding ligand |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200925 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210614 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210622 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210915 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220719 |